Navigation Links
SABCS: Loss of RB in triple negative breast cancer associated with favorable clinical outcome
Date:12/9/2011

SAN ANTONIOResearchers at the Thomas Jefferson University Hospital and Kimmel Cancer Center at Jefferson have shown that loss of the retinoblastoma tumor suppressor gene (RB) in triple negative breast cancer patients is associated with better clinical outcomes. This is a new marker to identify the subset of these patients who may respond positively to chemotherapy.

Today, no such marker is applied in care of triple negative breast cancer, and as a result, patients are all treated the same.

Agnieszka Witkiewicz, M.D., Associate Professor of Pathology, Anatomy and Cell Biology at Thomas Jefferson University, and Erik Knudsen, Ph.D., Professor of Cancer Biology and Deputy Director of Basic Science at Jefferson's Kimmel Cancer Center, discussed the findings at the 2011 CTRC‑AACR San Antonio Breast Cancer Symposium during a poster discussion.

"This is a step in trying to better direct treatment for patients with triple negative breast cancer," Dr. Knudsen said.

In general for cancer, loss of tumor suppressor genes is associated with poor clinical outcome. However, loss of RB in triple negative breast cancer patients appears to be a predictor of favorable clinical outcomes. This is because it changes the way tumor cells respond to therapy such that they end up becoming more sensitive to chemotherapy.

The researchers retrospectively evaluated the RB status and clinical outcome of a cohort of 220 patients diagnosed and treated at Thomas Jefferson University Hospital with chemotherapy. RB loss, they found, was associated with a longer overall survival. In contrast, patients with RB had worse survival.

"Triple negative breast cancer is the most deadly of breast cancers, with fast-growing tumors, that affects younger women," said Dr. Witkiewicz. "This work allowed us to identify a marker that could lead to better treatment for patients. It's about female personalized medicine."

Edith Mitchell, M.D., Professor of Medical Oncology at Jefferson, and Adam Ertel, Ph.D., a research instructor in the Department of Cancer Biology, were also involved in the study.

The next step for the researchers is a clinical trial at Jefferson to confirm their findings. Tumors of newly-diagnosed patients with triple negative breast cancer will be tested for the RB gene before they receive chemotherapy. After treatment, the data will be evaluated to determine the efficacy of directing future patient care.


'/>"/>
Contact: Steve Graff
stephen.graff@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. First genome sequencing clinical trial for triple negative cancer points to new treatments
2. First whole-genome sequencing clinical trials for triple-negative breast cancer presented
3. Deaths From Abuse of Painkillers Triple in a Decade: CDC
4. Cases of Legionnaires Disease Tripled in 10 Years
5. Triple therapy regime puts patients with leukemic form of cutaneous lymphoma in remission
6. Different subtypes of triple-negative breast cancer respond to different therapies
7. Treatment for Abuse of Anti-Anxiety Drugs Tripled Over 10 Years
8. Gene expression predicts chemotherapy sensitivity of triple-negative breast cancer
9. Nationwide utilization of virtual colonoscopy triples, study suggests
10. Philanthropic pledge triples funds for TGen ovarian cancer research
11. Multiple childbirth linked to increased risk of rare, aggressive triple-negative breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... 2016 , ... Dr. Philip Shindler, dentist in Agoura Hills , now ... past, many necessary dental treatments could require multiple appointments to complete. This could mean ... chair time. Not only could this be inconvenient, but it could also be overwhelmingly ...
(Date:5/2/2016)... Rhinebeck, NY (PRWEB) , ... May 02, 2016 , ... ... Valley, reopened for its 2016 guest season which runs through October. Omega is offering ... talks . , “There has never been such widespread interest in or ...
(Date:5/2/2016)... , ... May 02, 2016 , ... ... itself around major organs, such as the kidneys, liver and pancreas. If not ... M.D ., a board-certified physician in Internal Medicine, Medical Oncology and Palliative Care, ...
(Date:5/2/2016)... ... May 02, 2016 , ... Pregnancy Awareness Month offers a great time ... , “If you are ready to have a baby, it’s best to get ... Journal Babies is your Personal Conception & Pregnancy Organizer, written for women who plan ...
(Date:5/2/2016)... PARSIPPANY, N.J. (PRWEB) , ... May 02, 2016 ... ... - Healthcare Research & Analytics EVP and GM Jim Callandrillo and Duane ... during the 55th Annual Pharmaceutical Business Intelligence and Research Group (PBIRG) General ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... YORK , April 28, 2016 ... online consumer insights on healthcare, announced today that it ... their report Cool Vendor in Life Sciences, 2016, ... April 15, 2016.  The report focuses on life-science- oriented ... gain insight from patients and doctors, confirm medication ingestion, ...
(Date:4/28/2016)... FREMONT, Calif. , April 28, 2016 ... Enterprise Validation Lifecycle Management Solutions (VLMS) today ... products and services for sufferers of chronic ... management System to manage their corporate validation ... been seeking a software solution to manage ...
(Date:4/27/2016)... PARIS , le 27 Avril 2016 /PRNewswire/ ... chiffre d,affaires a progressé de +5% sur le ... ventes récurrentes de consommables  Croissance de ... Mauna Kea Technologies (Euronext : ... multidisciplinaire d,endomicroscopie confocale laser, annonce aujourd,hui son chiffre ...
Breaking Medicine Technology: